Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | 177Lu-girentuximab |
Trade Name | |
Synonyms | 177Lu-DOTA-cG250|Lutetium Lu-177 Girentuximab |
Drug Descriptions |
177Lu-girentuximab is a radioconjugate comprising the radionuclide Lutetium-177 linked to girentuximab, a monoclonal antibody that targets G250, which delivers radiation to tumor cells and potentially results in inhibition of tumor growth (PMID: 14960657, PMID: 22980441). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C66978 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
177Lu-girentuximab | 177Lu-girentuximab | 0 | 0 |
177Lu-girentuximab + Cabozantinib + Nivolumab | 177Lu-girentuximab Cabozantinib Nivolumab | 0 | 1 |
177Lu-girentuximab + Nivolumab | 177Lu-girentuximab Nivolumab | 0 | 1 |
177Lu-girentuximab + Peposertib | 177Lu-girentuximab Peposertib | 0 | 1 |